ARK Genomic Revolution ETF
ARKG
312 hedge funds and large institutions have $715M invested in ARK Genomic Revolution ETF in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 76 increasing their positions, 117 reducing their positions, and 44 closing their positions.
36% more call options, than puts
Call options by funds: $102M | Put options by funds: $74.8M
14% more capital invested
Capital invested by funds: $629M → $715M (+$85.4M)
3.14% more ownership
Funds ownership: 26.68% → 29.82% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 334 → 312 (-22)
35% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 117
39% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$59.3M |
| 2 |
Morgan Stanley
New York
|
+$56.7M |
| 3 |
Goldman Sachs
New York
|
+$25.5M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$9.29M |
| 5 |
Citigroup
New York
|
+$7.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$23.6M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$17.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.83M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$6.26M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$6.16M |
ARKG Hedge Fund Activity: Q3 2022 in Review
312 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2022, worth a combined $715M — up 14% from $629M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ARKG and 27 opened new positions — a net loss of 17 holders — while 117 trimmed existing stakes and 76 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $59.3M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $23.6M sold.
- 312 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2022, down from 334 in Q2 2022.
- Funds reported $715M of ARK Genomic Revolution ETF stock for Q3 2022, up 14% quarter-over-quarter.
- 27 funds opened new ARK Genomic Revolution ETF positions in Q3 2022 and 44 closed out, a net change of -17 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $59.3M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2022 was Avidity Partners Management, an estimated $23.6M sold.
Based on aggregated 13F filings for Q3 2022.